Please login to the form below

Not currently logged in
Email:
Password:

Michael Cola resigns as president of Shire Specialty Pharmaceuticals

Leaves to "explore new career opportunities and challenges”

Michael Cola - ShireShire's Michael Cola is to resign as president of the company's specialty pharmaceuticals business.

“With the company in a position of tremendous strength it is time for me to explore new career opportunities and challenges,” he said. “It has been an honour to work with my colleagues at Shire.”

Cola had been with Shire for seven years, joining as executive VP and general manager for the company's global therapeutic business units.

He assumed the role of president of the specialty pharmaceuticals business in 2006.

His role will be taken over by the company's CEO Angus Russell while the search for a new president is carried out.

Russell said: “As president of the SP business, Mike was instrumental in helping Shire transform itself from a company dominated by a single product in one market to a leading global biopharmaceutical company with a diversified product portfolio.”

Prior to joining Shire, Cola held several executive positions at pharma companies, including Merck,  AstraZeneca and Safeguard Scientifics.

3rd April 2012

Share

Related Hub content

    Your search did not contain any words. Please try again.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
DDB Remedy

Sixty years ago Bill Bernbach, Ned Doyle and Maxwell Dane gave the advertising industry a wake-up call.They introduced a new...

Latest intelligence

BL_Where_Now_20140721_CoverImage.jpg
3 Steps to Navigating Multichannel in Healthcare
You know about multichannel, but... where now? Download the 3 Steps to Navigating Multichannel in Healthcare ebook to learn what you should do next when planning your multichannel campaign....
Online Physician Communities
How can pharma develop a more customer-centric approach?
Business pressures and customer needs will force pharma to focus on multichannel marketing in the next few years...
Exploring MINT: Part 2 - Indonesia
In the second of a series of posts focusing on each of the ‘MINT’ markets, I take an in-depth look at the opportunities and challenges for pharma in Indonesia, with...